ABBV/ENTA—One thing the EP Vantage article didn’t mention: In addition to the six phase-3 trials to be submitted with the initial NDA in 2Q14, there are three ancillary phase-3 trials—one for HIHCV/HIV co-infection and two going head-to-head with Incivekr + peg/riba; these are the three trials shown at the bottom of #msg-93647264.
Market Data 
Markets 
AI
